The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jan. 17, 2023

Filed:

Dec. 31, 2020
Applicant:

Abbisko Therapeutics Co., Ltd., Shanghai, CN;

Inventors:

Fei Yang, Shanghai, CN;

Haibing Deng, Pudong New Area Shanghai, CN;

Haiyan Ying, Pudong New Area Shanghai, CN;

Hongping Yu, Shanghai, CN;

Zhui Chen, Shanghai, CN;

Yaochang Xu, Shanghai, CN;

Assignee:

ABBISKO THERAPEUTICS CO., LTD., Pudong New Area Shanghai, CN;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61P 35/00 (2006.01); C07D 471/04 (2006.01); C07D 491/052 (2006.01); C07D 495/04 (2006.01); C07D 513/04 (2006.01); A61K 31/505 (2006.01); C07D 239/84 (2006.01); A61K 31/517 (2006.01); A61K 31/506 (2006.01); A61K 31/519 (2006.01); C07D 475/00 (2006.01); A61K 31/437 (2006.01);
U.S. Cl.
CPC ...
C07D 471/04 (2013.01); A61K 31/437 (2013.01); A61K 31/505 (2013.01); A61K 31/506 (2013.01); A61K 31/517 (2013.01); A61K 31/519 (2013.01); A61P 35/00 (2018.01); C07D 239/84 (2013.01); C07D 475/00 (2013.01); C07D 491/052 (2013.01); C07D 495/04 (2013.01); C07D 513/04 (2013.01); Y02P 20/55 (2015.11);
Abstract

Provided are an FGFR4 inhibitor having the structure of formula (I), and a preparation method therefor and the use thereof. The compound has a very strong inhibitory effect on FGFR4 kinase activity and has a very high selectivity, and can be widely used in the preparation of a drug for treating cancers, especially prostate cancer, liver cancer, pancreatic cancer, esophageal carcinomas, gastric cancer, lung cancer, breast cancer, ovarian carcinomas, colon cancer, skin cancer, glioblastomas or rhabdomyosarcomas, and is expected to be developed into a new generation of FGFR4 inhibitor drugs.


Find Patent Forward Citations

Loading…